Study Shows Regularly Taking Aspirin Reduces the Chances of Dying From Prostate Cancer
A new study hints that men who have the habit of taking aspirin on a regular basis are less-likely to die from cancer of the prostate.
Researchers from the Harvard School of Medicine, Boston have released a report suggesting that men who are affected by prostate cancer and regularly take aspirin are less-likely to die from the cancer. Led by Dr. Christopher Allard, lead researcher and urologic oncology fellow at the University, the team of researchers state that chances of dying from the cancer can come down by as much as 40%.
This is certainly welcome news especially today where there seems to be a rise in new cases as well as death. The latest statistics from the American Cancer Society states that 220,800 new cases were reported for the year 2015, putting cancer of the prostate as the most common cancer in men. About 27,520 deaths occurred within the same period. The reports further indicate than 1 in every 7 men will be a victim of the cancer in his life, and that 6 out of 10 men aged 65 and above will suffer from the disease.
Aspirin, which has been seen to prevent or lower risk of death in other life-threatening conditions such as heart attacks, has been undergoing tests for quite a long time. Although the trials are still ongoing and there is still more room to be covered; for instance, testing whether the medication is effective in advanced or lethal cases, this recent news points to the right direction and is being received well by people.
According to the report, aspirin suppresses blood platelets which are affected by the cancer. Shielding the platelets affected by the cancer prevents the immune system from recognizing them but instead it sees the cancer and works to combat it. Thus, aspirin minimizes the adverse effects from the disease, lowering the risk and improving the survival rate.
During the presentation of the findings at the American Society of Clinical Oncology (ASCO) meeting held in San Francisco on January, 4th, the researchers clarified that they are yet to draw a direct connection showing cause and effect between death from cancer of the prostate and aspirin. This is because the study was based on observation rather than formal clinical trials that make comparison between actual use and placebo.
Dr. Sumanta Pal, an expert at ASCO and oncologist at City of Hope, Duarte, California says that the findings are quite interesting and will provoke the thoughts of many experts as well as victims. However, more needs to be done to ascertain that aspirin is indeed effective in reducing the chances of death as a result of prostate cancer.